15.2 Calciphylaxis & Radiation Tissue Injury

15.2 Calciphylaxis & Radiation Tissue Injury

Core Clinical Principle: Calcific uremic arteriolopathy (calciphylaxis) and late radiation tissue injury are both wounds of small-vessel failure: calcified, thrombosed subcutaneous arterioles in one, obliterative endarteritis in the other. Calciphylaxis carries 1-year mortality often reported at 50% or higher, and management centers on stopping triggers such as warfarin, correcting mineral metabolism, sodium thiosulfate, pain control, and careful wound care. Osteoradionecrosis is explained by the Marx hypovascular-hypocellular-hypoxic ("3H") principle, and hyperbaric oxygen is used selectively alongside surgical resection.

Both conditions punish aggressive, poorly planned surgery. Wound specialists must recognize them early, confirm the diagnosis when needed (biopsy for calciphylaxis when uncertain; biopsy to exclude recurrent tumor in irradiated tissue), and coordinate nephrology, oncology, surgery, and palliative care.

---

Calcific Uremic Arteriolopathy (Calciphylaxis / CUA)

Calcific Uremic Arteriolopathy (CUA), commonly designated calciphylaxis, is a devastating small-vessel calcification syndrome characterized by progressive mural calcification, intimal fibroblastic hyperplasia, and endovascular microthrombus formation within small- to medium-sized dermal and subcutaneous arterioles (roughly 40 to 600 μm in diameter). The resulting downstream ischemia produces excruciatingly painful subcutaneous ischemic plaques, hemorrhagic necrosis, and extensive non-healing ulcerations.

+-------------------------------------------------------------------------------------------------+
|                        MOLECULAR & BIOCHEMICAL CASCADE OF CALCIPHYLAXIS                         |
+-------------------------------------------------------------------------------------------------+
| 1. CHRONIC KIDNEY DISEASE-MINERAL BONE DISORDER (CKD-MBD)                                       |
|    • Hyperphosphatemia, hypercalcemia, and abnormal PTH (high or very low) promote calcification |
|    • Secondary Hyperparathyroidism -> Sustained parathyroid hormone (PTH) elevation             |
|    • Systemic chronic inflammation (elevated IL-6, TNF-alpha) + Hypoalbuminemia                 |
+-------------------------------------------------------------------------------------------------+
                                                │
                                                ▼
+-------------------------------------------------------------------------------------------------+
| 2. VASCULAR SMOOTH MUSCLE PHENOTYPIC TRANSDIFFERENTIATION                                       |
|    • Elevated extracellular phosphate enters vascular smooth muscle cells (VSMCs) via Pit-1     |
|    • Upregulation of osteogenic transcription factors (Runx2 / Cbfa1, Msx2, Osterix)            |
|    • VSMCs transform from contractile phenotype into bone-forming osteoblast-like cells         |
|    • Secretion of extracellular matrix vesicles loaded with Calcium and Hydroxyapatite          |
+-------------------------------------------------------------------------------------------------+
                                                │
                                                ▼
+-------------------------------------------------------------------------------------------------+
| 3. LOSS OF ENDOGENOUS CALCIFICATION INHIBITORS (THE WARFARIN LINK)                              |
|    • Matrix Gla Protein (MGP) is a key local inhibitor of vascular calcification                 |
|    • MGP requires Vitamin K-dependent gamma-glutamyl carboxylation to become biologically active|
|    • WARFARIN inhibits Vitamin K Epoxide Reductase (VKOR) -> Accumulation of uncarboxylated MGP|
|      --> Weakened calcification defense -> Medial mineral deposition in small arterioles         |
+-------------------------------------------------------------------------------------------------+
                                                │
                                                ▼
+-------------------------------------------------------------------------------------------------+
| 4. ENDOVASCULAR OCCLUSION & ISCHEMIC PANNICULITIS                                               |
|    • Concentric medial arteriolar calcification (40-600 μm vessels) + Subintimal fibroplasia   |
|    • Endovascular fibrin thrombus formation -> Complete luminal microvascular occlusion        |
|    • Subcutaneous fat ischemia -> Lobular panniculitis -> Stellate eschar & fatal sepsis risk   |
+-------------------------------------------------------------------------------------------------+

Epidemiology & Lethality

• Prevalence: CUA affects approximately 1% to 4% of the end-stage renal disease (ESRD) population, almost exclusively in patients undergoing chronic hemodialysis or peritoneal dialysis. Rare non-uremic calciphylaxis occurs in the setting of primary hyperparathyroidism, severe liver disease, rapid-weight-loss bariatric surgery, or malignancy.
• Lethality: The clinical prognosis is dismal: 1-year mortality ranges from 50% to 80%. Sepsis from infected wounds is the leading cause of death secondary to bacterial colonization and deep infection of extensive, necrotic, ulcerated eschars.

Biochemical & Clinical Risk Factors

1. Hyperphosphatemia and Hypercalcemia: Persistent hyperphosphatemia and hypercalcemia (historically summarized as a high calcium-phosphate product) favor calcium-phosphate deposition in vessel walls, although many patients with calciphylaxis have normal values at diagnosis.
2. Parathyroid Hormone Extremes: Severe secondary hyperparathyroidism mobilizes calcium and phosphate from bone, and oversuppressed PTH with adynamic bone disease has also been linked to calciphylaxis.
3. Hypoalbuminemia: Serum albumin < 3.5 g/dL reflects malnutrition and chronic systemic inflammation, reducing the serum solubility of mineral complexes.
4. Female Sex & Obesity: Substantially higher prevalence in females (roughly twice as common in women in many series) and patients with a high body mass index ($BMI > 30\text{ kg/m}^2$), driven by abundant subcutaneous adipose tissue containing dense arteriolar networks.

The Warfarin Mechanism: A Major Modifiable Risk Factor

Warfarin (Coumadin) is one of the most important modifiable risk factors for calciphylaxis.

• Physiological Mechanism: Vascular calcification is actively restrained in healthy human tissue by Matrix Gla Protein (MGP), a small, 84-amino acid protein synthesized by vascular smooth muscle cells and chondrocytes. MGP binds hydroxyapatite crystal nuclei and inhibits bone morphogenetic protein-2 (BMP-2), preventing soft-tissue and vascular wall mineralization.
• Requirement for Vitamin K: To achieve biological activity, MGP must undergo post-translational gamma-glutamyl carboxylation catalyzed by gamma-glutamyl carboxylase, a process requiring reduced Vitamin K as an essential cofactor.
• Warfarin Antagonism: Warfarin blocks Vitamin K epoxide reductase (VKOR), exhausting reduced Vitamin K reserves. Consequently, MGP remains in an inactive, uncarboxylated state (ucMGP). In the absence of functional carboxylated MGP, vascular calcification proceeds unchecked. In patients with ESRD who already possess a deranged calcium-phosphate milieu, warfarin exposure is strongly associated with developing CUA.

==================================================================================
PRACTICE POINT: WARFARIN IN CALCIPHYLAXIS
==================================================================================
When calciphylaxis is suspected, stop warfarin whenever it is safe to do so.

If anticoagulation remains necessary (e.g., high-risk atrial fibrillation or prior
thromboembolism), consider a non-vitamin K alternative such as heparin or a
direct oral anticoagulant chosen for kidney function; mechanical heart valves
need individualized cardiology input because DOACs are not an option.
==================================================================================

Clinical Presentation & Anatomy

• Prodromal Neuro-Ischemic Pain: Excruciating, unremitting, burning pain is the earliest and most prominent symptom, characteristically preceding visible cutaneous breakdown by several days to weeks. The pain is out of proportion to early physical findings.
• Early Cutaneous Lesions: Deep-seated, indurated, tender subcutaneous plaques or nodules. Overlying skin displays a livedo reticularis or livedo racemosa pattern—an irregular, violaceous, net-like discoloration reflecting microvascular congestion.
• Advanced Cutaneous Lesions: As endovascular thrombosis occludes the microcirculation, the plaques evolve into non-blanching violaceous purpura, hemorrhagic bullae, and focal cutaneous infarction. The center demarcates into a characteristic jagged, stellate, black, leathery, adherent eschar surrounded by an advancing violaceous ischemic rim.
• Anatomical Distribution: CUA exhibits an overwhelming tropism for adiposity-rich anatomical regions: the anterior thighs, lower abdomen, buttocks, breasts, and calves. Distal acral forms (involving digits or toes) carry a somewhat lower mortality than proximal central lesions.

Diagnostic Biopsy: Deep Punch or Incisional Technique

While clinical presentation in an ESRD patient is often strongly suggestive, histological confirmation is the gold standard when diagnosis is uncertain:

• Biopsy Protocol: Superficial punch biopsies often miss the diagnosis because calciphylaxis is a disease of subcutaneous arterioles. Sample with a deep punch biopsy or an incisional (wedge) biopsy that reaches well into the subcutaneous fat. Biopsy remains debated, because the site can ulcerate or become infected and a negative biopsy does not exclude the disease.
• Histopathological Triad:
  1. Concentric Medial Arteriolar Calcification: Microcalcification within the internal elastic lamina and tunica media of small subcutaneous arterioles (diameter roughly 40–600 μm).
  2. Subintimal Fibroblastic Proliferation: Hyperplasia of subintimal myofibroblasts and endothelial swelling.
  3. Endovascular Fibrin Thrombi: Luminal microthrombosis leading to downstream tissue infarction and ischemic lobular panniculitis (adipocyte necrosis with foamy macrophage infiltration).
• Special Histochemical Stains: Calcification is confirmed on tissue sections using the Von Kossa stain (silver reduction demonstrating dense black calcium phosphate precipitates) or Alizarin Red stain (which stains calcium deposits bright orange-red).
• Biopsy Risk: Performing a biopsy creates a mechanical skin defect that can itself fail to heal or become a nidus for fatal bacterial infection. Therefore, biopsy should be performed at the viable, indurated margin—never through the necrotic center—under sterile surgical technique.

---

Multimodal Medical Management of Calciphylaxis

No therapy has randomized-trial proof of benefit, so care relies on a coordinated multimodal plan spanning nephrology, wound care, dermatology, nutrition, and pain or palliative care:

+-------------------------------------------------------------------------------------------------+
|                        MULTIMODAL THERAPEUTIC REGIMEN FOR CALCIPHYLAXIS                         |
+-------------------------------------------------------------------------------------------------+
| 1. SODIUM THIOSULFATE (STS) INFUSION (Widely Used; Off-Label, Observational Evidence)           |
|    • Dose: 25 grams IV (in 100 mL D5W or Normal Saline) administered over 30-60 minutes         |
|    • Timing: During the final 30-60 minutes of hemodialysis, 3 times weekly (or post-dialysis)  |
|    • Mechanisms:                                                                                |
|      - Calcium Chelation: Proposed to form soluble calcium thiosulfate complexes that are       |
|        more soluble than calcium phosphate and are cleared across the dialyzer membrane         |
|      - Potent Antioxidant: Directly scavenges reactive oxygen species (ROS), reversing          |
|        endothelial dysfunction and lipid peroxidation                                           |
|      - Vasodilation: Promotes endogenous endothelial nitric oxide release, improving perfusion  |
|    • Adverse Effects: High anion-gap metabolic acidosis, nausea/vomiting, volume overload       |
+-------------------------------------------------------------------------------------------------+
                                                │
                                                ▼
+-------------------------------------------------------------------------------------------------+
| 2. MINERAL & BONE METABOLISM NORMALIZATION                                                      |
|    • Calcimimetics: Oral Cinacalcet (Sensipar) to suppress parathyroid hormone (PTH) to         |
|      KDIGO range (about 2 to 9 times the upper normal limit) without causing hypocalcemia      |
|    • Phosphate Binders: Non-calcium, non-aluminum binders (Sevelamer carbonate, Lanthanum)      |
|      --> Stop calcium-based binders (calcium acetate, calcium carbonate)                       |
|    • Low-Calcium Dialysate Bath: Lower dialysate calcium (commonly about 2.0 mEq/L)             |
|    • Discontinue active Vitamin D analogs (calcitriol, paricalcitol) to prevent hypercalcemia   |
+-------------------------------------------------------------------------------------------------+
                                                │
                                                ▼
+-------------------------------------------------------------------------------------------------+
| 3. IATROGENIC TRIGGER REVERSAL & SURGICAL CONSIDERATIONS                                        |
|    • Stop warfarin when safe; use a non-vitamin K anticoagulant if anticoagulation is needed     |
|    • Aggressive Pain Control: Scheduled opioids, gabapentinoids, lidocaine infusions            |
|    • Avoid Local Trauma: No subcutaneous injections (insulin, heparin) into indurated areas     |
|    • DEBRIDEMENT: Individualize; many experts avoid aggressive excision of stable, dry           |
|      eschar, while others debride to reduce infection risk; observational data are conflicting; |
|      keep stable eschar dry, use gentle methods, and remove infected or liquefied necrosis    |
|      surgically when it drives sepsis                                                           |
|    • Hyperbaric Oxygen Therapy (HBOT): 2.0 to 2.4 ATA for 90 min (adjunct for refractory wounds)|
+-------------------------------------------------------------------------------------------------+

---

Radiation Necrosis & Osteoradionecrosis (ORN)

Therapeutic ionizing radiation delivers targeted cellular destruction to malignant neoplasms, but induces collateral, permanent microvascular and cellular damage to surrounding normal tissues. This chronic damage culminates in late radiation tissue injury (radiation necrosis) and osteoradionecrosis (ORN).

Pathophysiology: The Marx "3H" Principle

Historically, osteoradionecrosis was viewed as a bacterial osteomyelitis. In 1983, Dr. Robert E. Marx proposed that radiation-induced bone and soft-tissue necrosis is primarily a non-healing wound of hypoxic, hypocellular, hypovascular tissue (the "3H" principle), with microorganisms acting as contaminants rather than the cause. Newer models also emphasize radiation-induced fibrosis:

+-------------------------------------------------------------------------------------------------+
|                                 THE MARX "3H" PRINCIPLE                                         |
+-------------------------------------------------------------------------------------------------+
| 1. HYPOVASCULAR                                                                                 |
|    • Radiation generates free radicals -> Endothelial cellular DNA damage and senescence       |
|    • Progressive obliterative endarteritis, subendothelial foam cell proliferation, thrombosis |
|    • Capillary dropout -> Massive permanent reduction in functional microvascular density      |
+-------------------------------------------------------------------------------------------------+
                                                │
                                                ▼
+-------------------------------------------------------------------------------------------------+
| 2. HYPOCELLULAR                                                                                 |
|    • Radiation induces apoptosis and irreversible cell cycle arrest in local parenchymal cells  |
|    • Destruction of local osteoblasts, osteocytes, osteoclasts, and normal dermal fibroblasts   |
|    • Emergence of senescent, radiation-induced myofibroblasts locked in dysfunctional fibrosis  |
+-------------------------------------------------------------------------------------------------+
                                                │
                                                ▼
+-------------------------------------------------------------------------------------------------+
| 3. HYPOXIC                                                                                      |
|    • Obliterative microvascular loss lowers tissue oxygen tension well below normal values         |
|    • Severe, chronic tissue hypoxia arrests aerobic metabolism, halting macrophage phagocytosis |
|      and stopping normal fibroblast collagen synthesis and re-epithelialization                 |
+-------------------------------------------------------------------------------------------------+

Clinical Manifestations of Radiation Injury

• Chronic Radiation Dermatitis: Poikiloderma (mottled hyperpigmentation and hypopigmentation, epidermal atrophy, and dense arborizing telangiectasias), dermal woody induration, loss of cutaneous appendages (alopecia, anhidrosis), and recurrent breakdown from minor mechanical shear.
• Osteoradionecrosis (ORN): Exposed, non-healing, devitalized bone that persists for more than 3 months in a previously irradiated radiation field, in the absence of local recurrent malignancy. The most common site is the mandible following head and neck radiotherapy (radiation dose typically exceeding 60 to 70 Gy), followed by the pelvic bones (sacrum, pubic symphysis) following pelvic radiation for cervical, prostate, or rectal carcinoma.

The Marx Hyperbaric Oxygen Protocol for Osteoradionecrosis

Because the underlying pathology is microvascular dropout, surgery in irradiated tissue heals poorly. Hyperbaric Oxygen Therapy (HBOT) acts as an angiogenic stimulus, establishing an oxygen gradient that stimulates vascular endothelial growth factor (VEGF), recruits circulating endothelial progenitor cells, and increases capillary density and tissue oxygen tension in irradiated tissue (in Marx's work, oxygen tension rose to roughly 80% of non-irradiated tissue values). Randomized evidence is mixed: a French multicenter trial of HBOT for established mandibular ORN (Annane et al., 2004) stopped early without showing benefit, and the HOPON trial (2019) did not show a clear benefit for preventing ORN after dental extractions, so indications are individualized.

THE MARX HYPERBARIC OXYGEN PROTOCOL FOR ORN (STAGING & SCHEDULE)
==================================================================================
Marx Stage I ORN (Early bone exposure, responsive to HBOT):
  • Initial HBOT: 30 sessions (dives) at 2.4 ATA for 90 minutes each (100% O2).
  • Assessment: If soft tissue shows full resolution and bone heals, complete an
    additional 10 post-treatment sessions (40 total dives).

Marx Stage II / Stage III ORN (Refractory, pathological fracture, or requiring resection):
  • Pre-Operative HBOT: 30 sessions at 2.4 ATA for 90 minutes.
  • Definitive Surgery: Radical resection of necrotic, non-bleeding bone to viable,
    bleeding margins, with immediate or delayed vascularized free-tissue reconstruction.
  • Post-Operative HBOT: 10 sessions at 2.4 ATA for 90 minutes post-operatively.
==================================================================================

The 30/10 schedule above follows the classic Marx staging protocol and the older 20/10 schedule is used before dental extraction in irradiated jaws; both remain widely taught even though trial results are mixed.